Oncoclínicas faces potential total replacement of Board of Directors

Oncoclínicas (ONCO3) is facing significant governance changes following a request from the UBS Lumen Fundo de Investimento Financeiro em Ações, represented by EXA Capital Asset, to replace its entire Board of Directors. The shareholder's proposal includes the dismissal of current members and the election of new members, with a plan to fix the board size at seven members.

Separately, the company has announced it will convene an Extraordinary General Meeting (AGE) to elect all members of its Board of Directors. This move follows the resignation of board member Paulo Roberto Belem Junior. Due to the company's use of a multiple voting system, the resignation of a single member necessitates a full reelection of the entire board rather than the appointment of a single successor.

The specific reasons for Belem Junior's resignation have not been disclosed, and the company has not yet deliberated on the specific timing for the shareholder-requested meeting.